反应详情

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: 1H NMR (CDCl3) δ 0.93–1.09, 1.28–1.39, 2.35–2.43, 2.60–2.67, 2.99–3.05, 3.22–3.29, 4.70, 5.04, 5.44–5.49, 7.23–7.32; MS (ESI+) for C18H20BrN3O m/z 374 (M+H)+.